Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
Cancer Cell. 2014 Apr 14;25(4):469-83. doi: 10.1016/j.ccr.2014.03.006.
MicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.
microRNA 失调在人类结直肠癌(CRC)中很常见,但尚不清楚它是否代表旁观者事件,还是实际上在体内驱动肿瘤进展。我们表明,miR-135b 的过表达是由 APC 缺失、PTEN/PI3K 通路失调和 SRC 过表达在小鼠和人类中触发的,并促进肿瘤转化和进展。我们表明,miR-135b 的上调在散发性和炎症性肠病相关的人类 CRC 中很常见,并且与肿瘤分期和不良临床结局相关。在 CRC 小鼠模型中抑制 miR-135b 通过控制参与增殖、侵袭和凋亡的基因来减少肿瘤生长。我们将 miR-135b 鉴定为致癌途径的关键下游效应因子和 CRC 治疗的潜在靶点。